retinal vein occlusion
Conditions
Interventions
Trade Name: avastin
Product Name: Bevacizumab
Pharmaceutical Form: Eye drops, powder and solvent for solution
Sponsors
CHRU Montpellier - Direction de la Recherche
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Age included between 18 years and 85 years OVCR recent diagnosis (=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Leukaemia, Myelome, Thrombophlebite, Disease of Vaquez, Disease of Osler, Disease of Behçet Amblyopic eye Diabetic maculopathie, Retinopathie diabetic Occlusion of the central artery of the associated retina (OACR) or Occlusion of the cilio-retinal artery Occlusion of branch of the central vein of the retina ( OBVCR) Other treatment of the OVCR undertaken before the inclusion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Evaluate the efficiency of premature covercare of the OVCR including a series of 3 intravitreal injections of Bevacizumab;Secondary Objective: Evaluation of the quality of visual function by means of a standardized questionnaire Evaluation of the oedema maculaire in OCT (Tomography in Optical Coherence) Evaluation and comparison of the tolerance of the treatment by Bevacizumab Research of complications of the OVCR;Primary end point(s): gain of visual acuteness measured in 6 months after the inclusion blind according to the international standards ETDRS and secondarily converted in acuteness logMAR. | — |
Countries
France
Outcome results
None listed